<DOC>
	<DOCNO>NCT03095703</DOCNO>
	<brief_summary>The aim study investigate effect sirolimus progression intestinal adenoma patient FAP assess safety treatment .</brief_summary>
	<brief_title>Sirolimus Familial Adenomatous Polyposis ( FAP )</brief_title>
	<detailed_description>SUMMARY Rationale : Due presence numerous colorectal polyp , nearly patient familial adenomatous polyposis ( FAP ) develop colorectal cancer ( CRC ) average age 45 year , leave untreated . Therefore , prophylactic colectomy recommend . After surgery , adenomas likely reappear pouch rectum . Recently , study APC-deficient mouse show mTOR inhibitor sirolimus cause intestinal tumour cell undergo growth arrest differentiation could even lead regression polyp . In current practice , sirolimus use immunomodulator patient renal transplantation . Sirolimus never investigate patient FAP . The hypothesis study sirolimus could lead regression intestinal polyp patient FAP . Objective : The aim study investigate effect sirolimus progression intestinal adenoma patient FAP assess safety treatment . Study design : A prospective phase II pilot study follow-up 6 month . Study population : Five patient FAP select invite study participation . Patients need 18 year old , genetically confirm APC mutation classical FAP phenotype subtotal colectomy ileo-rectal anastomosis ( IRA ) total colectomy ileo-anal pouch anastomosis ( IPAA ) severe polyposis . Intervention : All patient receive sirolimus duration study , trough level target range 5-8 ng/ml . Main study parameters/endpoints : The main study parameter effect sirolimus size 5 mark polyp safety treatment . Safety outcome assess summary analysis adverse event , clinical laboratory abnormality regular physical examination . Additional parameter effect number polyp , global polyp burden , histopathology patient-reported quality life . Cell proliferation immunohistochemistry mTOR target healthy intestinal mucosa adenomatous tissue assess . Nature extent burden risk associate participation , benefit group relatedness : At baseline three monthly visit medical history take physical examination perform , well laboratory test HRQoL questionnaire . Trough level test sirolimus measure day 7 start study drug weekly therapeutic range achieve , next trough level measure 3 6 month follow-up . Finally , monthly telephone check-ups carry . LGI endoscopies do baseline 6 month . For study , patient include severe rectal pouch polyposis expect indication invasive surgery short-term base less invasive alternative therapy available .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Adenomatous Polyposis Coli</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>â‰¥ 18 year A genetically confirm APC mutation Classical FAP phenotype ( 1001000 colorectal adenomatous polyp ) Subtotal colectomy ileorectal anastomosis ( IRA ) total colectomy ileoanal pouch anastomosis ( IPAA ) Severe rectal pouch polyposis , define &gt; 25 polyp amenable complete removal ( InSiGHT 2011 Staging System score 3 ) Fertile patient must use effective contraception study treatment 12 week study treatment Inability give inform consent Participation another interventional clinical trial Subjects pregnant breastfeeding , prove negative pregnancy test female childbearing potential Prior pelvic irradiation Invasive malignancy past 5 year Subjects HIV positive Subjects severe systemic infection , current within 2 week prior study start Subjects know severe restrictive obstructive pulmonary disorder Known sucrase insufficiency , isomaltase insufficiency , fructose intolerance , glucose malabsorption , galactose malabsorption , galactose intolerance Lapplactase deficiency History pulmonary embolism deep venous thrombosis Major surgery less equal 2 week prior enrollment plan surgery within treatment period Active postoperative complication , e.g . infection , delay wound heal History hypersensitivity sirolimus drug similar chemical class Regular NSAID use ( define twice week 4 consecutive week ) within 3 month prior baseline Use FAP direct drug therapy ( accept discontinue 3 month prior start study ) Subjects require systemic anticoagulation Comedication could interact sirolimus Abnormal laboratory result ( assess within 14 day prior start study drug )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sirolimus</keyword>
	<keyword>Intestinal adenoma</keyword>
</DOC>